Accendra Health (ACH) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
15 Jul, 2026Company overview and business model
Operates as a nationwide provider of products, technology, and services supporting health beyond the hospital for millions annually.
Connects patients, providers, and insurers, focusing on chronic, complex, and acute health conditions.
Offers home healthcare equipment, disposable medical supplies, and integrated services across diabetes, respiratory therapy, sleep apnea, ostomy, wound care, urology, and incontinence.
Generates revenue through fee-for-service and capitation arrangements with government and commercial payors.
Utilizes technology for web portals, electronic ordering, and claims processing to improve efficiency and reduce costs.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for general corporate and working capital purposes, with temporary investment prior to use.
Risk factors and disclosures
Faces risks from competitive and pricing pressures, customer concentration, and dependence on key vendors and third parties.
Exposed to regulatory, legal, and compliance risks, including stringent healthcare regulations and potential investigations.
Subject to risks from cyberattacks, information system failures, and public health crises.
Financial condition may be impacted by contract terminations, reimbursement uncertainties, and substantial indebtedness.
Market price volatility and economic conditions may affect demand and receivables.
Latest events from Accendra Health
- Q2 2026 featured a 10.1% revenue drop, major debt reduction, and CEO succession plans.ACH
Q2 2026 - All proposals passed as the company advances its home-based care strategy nationwide.ACH
AGM 2026 - Q1 2026 revenue fell 6.8% to $627.8M, with a $1.5B balance sheet reset to boost liquidity.ACH
Q1 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ACH
Proxy filing - Shareholders to vote on directors, auditor, executive pay, and expanded equity plan amid strategic transformation.ACH
Proxy filing - 2026 guidance projects $2.55–$2.65B revenue, $335–$355M EBITDA, and strong cash flow.ACH
Q4 2025 - Q3 revenue up 5% to $2.7B, driven by Patient Direct and $198M debt reduction.ACH
Q3 2024 - Q2 revenue up 4–4.2% to $2.67–$2.7B; Rotech deal announced; 2024 outlook reaffirmed.ACH
Q2 2024 - $1.36B Rotech deal expands Patient Direct, targets $5B revenue, $50M synergies by year three.ACH
M&A Announcement